Member Info for seethreeIPO

Sounds like some Russian troops have "finished their exercises and moving away from the border" If confirmed and is a meaningful de-escalation expect to see all 'riskier' investments continue to rise.

typo - "this is significantly de-risked in my opinion"

RX, yeah but I did sell quite a lot of my investment north of 200p, in various trades. However, any previous profits made have no bearing on my decision to increase the holding again today. At this price and with the cancer developments not significantly
de-risked in my opinion, the price has never been better. I am waiting on target prices to be hit from other investments and much of those profits will be going back here if this price stays at or below where it is today. Incredibly opportunity IMHO.

rxdav - I bought my most significant tranche at 12p........

For anyone that is thinking about topping up or going in for the first time here's the level two data right now

Four MMs on 53 and only one on 55 - Looks tasty.

Depth 8
11:42 JBER 5,000 53
12:03 MREX 5,000 53
11:41 SCAP 5,000 53
12:16 WINS 5,000 53
11:39 SING 5,000 52
08:25 PMUR 5,000 49
11:04 STFL 5,000 47
12:04 PEEL 5,000 45
8 Depth
55 5,000 PEEL 12:04
56 5,000 STFL 11:04
57 5,000 SING 11:39
58 5,000 JBER 11:42
58 5,000 MREX 12:03
58 5,000 WINS 12:16
59 5,000 PMUR 08:25
63 5,000 SCAP 11:41

As a LTH I've added to my holding twice this morning, I'm certainly not exhausted! Also, there are lots of fairly decent buys coming in now, Avacta has been my most successful investment ever and I'm continuing to increase my holding, I've actually never felt better about doing that.

Just added a small amount to round out my holding, for the first time in two years I've increased my holding. Only by £2K but at this price it's crazy not to. Good old LSE showing it as a sell.

Hahahaha what a transparent moron! Tell us, oh wise one, what the value of the last fund raise was, what cash has been burned since then and what were the CEOs most recent comments about fundraising?

A hell of a lot less than you think would be the answer. We're talking about $200 for a drone operator, and that's if they don't have their own drone. A few hours editing, probably done internally but again hundreds not thousands. I'd be amazed if they're spending more than $1K per video for the update stuff....which in an investor relations budget is tiny.

Yeah I've never been able to see them on the phone view, but they're all there on the desktop browser view.

Hey Richob, yeah I was thinking this too. I know that Affimers were shown to have potential therapeutic use in CV19 patients but development was dropped ages ago......one wonders if that use case is not as dead as originally thought.

Interesting - what's AffiRX ? I don't recall seeing that before, could it be the BAMS kit...or something new in the pipe?

Can we please try and keep it civil guys? We’re looking at possibly the most exciting time for avacta for 2 years, come on.

On the subject of shorters they’re actually healthy in terms of the SP, and help provide a ‘bottom’ that can reverse a significant fall when they close their positions. Unfortunately they sometimes do foul up boards like this with very negative and often incorrect sentiment, but again this just balances ‘the force’.

Chill, enjoy the ride we’re embarking on again and be nice.

Many of us that invested long before Covid held this view back then, it was unusual to be able to both capitalise on an investment opportunity at the same time as effectively donating to a cancer research cause. Well done all.

I can't remember if this has been posted before, but here's the link to the trial website - 80 patients required.

https://www.patientwing.com/study/386687?showAdvancedDetails=true&layout=default&studySiteId=3232995

Riesgo, you are assuming that AVA6K has the same efficacy at the same dose as standard doxorubicin. However, due to the targeted nature of the drug conjugate, it may come to light that not only is it less toxic to healthy tissue, but also much more effective at destroying cancerous tissue at the same dose, or even lower doses as a standard doxorubicin treatment path. Therefore, the market would respond extremely positively to efficacy data showing as such.

Not necessarily true riesgo, it may be that due to the targeted nature of AVA a smaller dose will have far higher efficacy…..

Really??? Standard MAR notice

Avacta will be spending the next few days in small rooms with many institutional investors explaining what this means….the IIs won’t be buying 10k at a time they’ll be investing millions…..

Anything sub £5 is a gift! The AVA drug conjugate has been proved safe inside the body for the first time, and results are as expected following the mouse results, which were transformational in the treatment of cancer…:this is about as big as it gets.